Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Semaglutide (Ozempic / Wegovy) Targets the GLP-1 receptor only Weekly subcutaneous injection Clinical trials showed average weight loss of 15-17% of body weight FDA-approved for weight management (Wegovy) and type 2 diabetes (Ozempic) Tirzepatide (Mounjaro / Zepbound) Targets both GLP-1 and GIP receptors (dual agonist) Weekly subcutaneous injection Clinical trials showed average weight loss of 20-26% of body weight the highest of any medication FDA-approved for weight management (Zepbound) and type 2 diabetes (Mounjaro) The SURMOUNT-1 trial, published in the New England Journal of Medicine, demonstrated that tirzepatide at the highest dose (15mg) produced an average weight loss of 22.5% nearly one-quarter of body weight over 72 weeks
These changes reflect your eye adapting to healthier glucose levels rather than permanent damage
This article does not endorse or promote the use of any pharmaceutical product outside its approved labeling or in a manner inconsistent with the advice of a licensed prescriber
In RBCs, Prx2 can bind to Hb under OS conditions to stabilize its structure and prevent Hb aggregation [79]
US$ 24.21
US$ 26.40
US$ 21.92
